G-BA Innovation Committee supports the development of new medical guidelines

Care pathway for rare diseases

Tue, 2022 / 07 / 05
The Innovation Committee of the German Federal Joint Committee (G-BA) published a new funding announcement on June 27, 2022. Funding is now available for the development of new medical guidelines. This offer provides the opportunity to improve the care of special patient groups and pave the way for the market access of new drugs in indication areas with an unclear care context.

The funding is intended to support projects that aim to develop or refine guidelines for indications in which care is particularly challenging. The funded projects are expected to produce S3 guidelines in accordance with the requirements of the Association of the Scientific Medical Societies (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF). Interdisciplinary and interprofessional collaboration is a prerequisite for the development of these guidelines, as is the appropriate inclusion of the perspective of affected patients.

The funding is subject-specific, so the project to be funded must be assigned to one of the following subject areas:

  • Care for more common diseases with cross-sectoral coordination needs
  • Care for target groups with special needs (e.g. children, adolescents, elderly people and/or people in need of care, gender-specific characteristics, people with disabilities, ethical aspects)
  • Population health/public health (e.g. health promotion, prevention through lifestyle modification, protective measures, health communication)
  • Intensive care of critically ill patients

In particular, the development of guidelines for the care of target groups with special needs is intended to close gaps that exist in the care of many patients whose disease-related situation is extraordinary. This is especially true for children, palliative patients, but also for patients with orphan diseases. The lack of guidelines and thus of a clear care pathway complicates both the diagnosis and treatment of patients with rare conditions, often prolonging their suffering. The lack of clarity in the care situation in such indication areas additionally hinders the establishment of new drugs as a standard of care - although patients affected by rare diseases have an extraordinary need for effective and innovative therapeutic options.

The development of a guideline can help to structure the care context for patients within a specific indication, both in an early and late phase of the market access of a new drug. This enables a definite benefit assessment of the drug according to the latest scientific standards within the HTA process and thus helps affected individuals to receive the best treatment possible.

We at SKC encourage all stakeholders involved in the care of patients with special needs to take advantage of this offer from the G-BA. The deadline to apply for funding is September 27, 2022 at 12:00 pm. Applications can only be submitted via the internet portal of the commissioned project executing organization, the German Aerospace Center (Deutsches Zentrum für Luft und Raumfahrt e.V.). As a strategic healthcare consultancy with focus on rare diseases and their therapies, we are happy to support our clients in the analysis of complex care situations and in the realization of projects to improve the care reality of patients in Germany.

Source: Förderbekanntmachung Versorgungsforschung – Medizinische Leitlinien (MedLL) (in German language)

About the author

Ihr Ansprechpartner  Sebastian  Vinzens
Sebastian Vinzens
M.Sc. Drug Research and Development
Fon: +49 511 64 68 14 0 – 0
Fax: +49 511 64 68 14 18
to the top